Shanghai Junshi Bio to Invest $50 Million in Coherus, its US Partner

Shanghai Junshi Bio will make a $50 million strategic investment in Coherus BioSciences, a San Francisco area biosimilar commercialization company. Yesterday, Coherus announced it would acquire US-China rights to Junshi's anti-PD-1 antibody (and several other candidates) in a deal worth up to $1.1 billion, including a $150 million upfront payment to Junshi. At the time, nothing was said about the $50 million Junshi investment in Coherus. Junshi's Tuoyi (toripalimab) is the first China-developed anti-PD-1 antibody approved in China . More details.... Stock Symbols: (HK: 1877; SH: 688180) (NSDQ: CHRS) Share this with colleagues: // //
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.